Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WR 279,396 in Cutaneous Leishmaniasis
NCT01140191Phase 2Terminated
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Sep 2013
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of WR 279,396 in cutaneous leishmaniasis (CL), sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Number of Adverse Events at 3 months. Started Sep 2013; status: terminated.
02
Drugs
WR 279,396
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT01140191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01140191.